BR112022017308A2 - Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral - Google Patents

Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral

Info

Publication number
BR112022017308A2
BR112022017308A2 BR112022017308A BR112022017308A BR112022017308A2 BR 112022017308 A2 BR112022017308 A2 BR 112022017308A2 BR 112022017308 A BR112022017308 A BR 112022017308A BR 112022017308 A BR112022017308 A BR 112022017308A BR 112022017308 A2 BR112022017308 A2 BR 112022017308A2
Authority
BR
Brazil
Prior art keywords
bacterial strains
oral use
probiotic bacterial
composition including
antiviral action
Prior art date
Application number
BR112022017308A
Other languages
English (en)
Inventor
Biffi Andrea
FIORE Walter
Original Assignee
Sofar Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sofar Spa filed Critical Sofar Spa
Publication of BR112022017308A2 publication Critical patent/BR112022017308A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO QUE COMPREENDE LACTOFERRINA E CEPAS BACTERIANAS PROBIÓTICAS PARA USO ORAL COM AÇÃO ANTIVIRAL. A presente invenção refere-se a uma composição que compreende lactoferrina e, opcionalmente, cepas bacterianas probióticas e/ou N-acetilcisteína e/ou ácido hialurônico para uso oral como agente antiviral, de preferência para uso no tratamento de infecções virais do sistema respiratório por um SARS-coronavírus (por exemplo, COVID-19).
BR112022017308A 2020-03-09 2021-03-09 Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral BR112022017308A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102020000005011A IT202000005011A1 (it) 2020-03-09 2020-03-09 Lattoferrina per uso orale ad azione antivirale
PCT/IB2021/051959 WO2021181276A1 (en) 2020-03-09 2021-03-09 Composition comprising lactoferrin and probiotic bacterial strains for oral use with antiviral action

Publications (1)

Publication Number Publication Date
BR112022017308A2 true BR112022017308A2 (pt) 2022-10-11

Family

ID=70804945

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022017243A BR112022017243A2 (pt) 2020-03-09 2020-10-15 Lactoferrina para uso oral com ação antiviral
BR112022017308A BR112022017308A2 (pt) 2020-03-09 2021-03-09 Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022017243A BR112022017243A2 (pt) 2020-03-09 2020-10-15 Lactoferrina para uso oral com ação antiviral

Country Status (11)

Country Link
US (2) US20230080695A1 (pt)
EP (2) EP4117711A2 (pt)
JP (2) JP2023516461A (pt)
CN (2) CN115697382A (pt)
AU (2) AU2020292850A1 (pt)
BR (2) BR112022017243A2 (pt)
CA (2) CA3174706A1 (pt)
IL (2) IL295528A (pt)
IT (1) IT202000005011A1 (pt)
MX (2) MX2022010874A (pt)
WO (2) WO2020250209A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2593452A (en) * 2020-03-16 2021-09-29 Mead Johnson Nutrition Co Use of lactoferrin
IT202000009430A1 (it) * 2020-04-29 2021-10-29 Tdc Tech Dedicated To Care Srl Composizione per la prevenzione e/o il trattamento delle infezioni delle vie respiratorie
US20230149515A1 (en) * 2020-04-29 2023-05-18 The Regents Of The University Of Michigan Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof
US20240016901A1 (en) * 2020-05-28 2024-01-18 The Regents Of The University Of Michigan Compositions and methods for preventing and treating sars-cov-2 infection
WO2022162254A1 (es) * 2021-02-01 2022-08-04 Dermopartners,S.L. Composición para su uso en forma de gotas nasales y nebulizadores como antiviral
WO2022172523A1 (ja) * 2021-02-09 2022-08-18 森永乳業株式会社 プラズマサイトイド樹状細胞活性化用組成物
CN120860183A (zh) * 2021-08-31 2025-10-31 合生元（广州）健康产品有限公司 用于抑制冠状病毒的组合物及其应用
KR102737719B1 (ko) * 2021-09-27 2024-12-04 주식회사 프로바이오닉 신규한 락토바실러스 플란타럼 Probio 88, 이의 추출물 및 조성물
PE20251066A1 (es) 2022-07-20 2025-04-09 Frimline Private Ltd Composicion farmaceutica que proporciona efecto mucolitico
WO2024149375A1 (en) * 2023-01-13 2024-07-18 The Chinese University Of Hong Kong Synbiotic compositions for improving immunity and for treating atopic dermatitis
CN116509821A (zh) * 2023-03-07 2023-08-01 广州见华医学科技有限公司 一种乳铁蛋白贴剂在制备用于冠状病毒引起感染性疾病治疗药物中的用途
CN117018169A (zh) * 2023-10-07 2023-11-10 广州菲勒生物科技有限公司 一种预防呼吸道病毒感染的营养组合物制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06316529A (ja) * 1991-12-03 1994-11-15 Imuno Japan:Kk レンチウイルス感染に随伴する日和見感染症の治療予 防用医薬組成物
JPH1171301A (ja) * 1997-08-29 1999-03-16 Morinaga Milk Ind Co Ltd 抗動物感染性ウイルス剤及び飼料
AU4486501A (en) * 2000-03-27 2001-10-08 Pharming Intellectual Property Bv High dosage parenteral administration of lactoferrin
JP2004083487A (ja) * 2002-08-27 2004-03-18 Morinaga Milk Ind Co Ltd 抗ウイルス組成物及びウイルス感染症予防・治療用組成物
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US20090196921A1 (en) * 2008-02-06 2009-08-06 The Procter & Gamble Company Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition
IT1392672B1 (it) * 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
EP2493336A1 (en) * 2009-10-29 2012-09-05 Nestec S.A. Nutritional compositions comprising lactoferrin and probiotics and kits of parts thereof
KR101235561B1 (ko) * 2010-12-09 2013-03-21 주식회사 제일바이오 항바이러스 및 항균 활성을 갖는 락토바실러스 플란타룸 ｃｌｐ-1 균주 및 이를 포함하는 생균제
EP3419629A4 (en) * 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
WO2018191073A1 (en) * 2017-04-12 2018-10-18 The Uab Research Foundation Inhaled respiratory probiotics for lung diseases of infancy, childhood and adulthood
US11376311B2 (en) * 2017-11-02 2022-07-05 Colorado Seminary, Owner and Operator of University of Denver Methods of treating microbial infection and inflammation

Also Published As

Publication number Publication date
US20230330164A1 (en) 2023-10-19
CA3174706A1 (en) 2020-12-17
MX2022010874A (es) 2022-10-07
WO2021181276A1 (en) 2021-09-16
EP4117711A2 (en) 2023-01-18
US20230080695A1 (en) 2023-03-16
AU2020292850A1 (en) 2022-09-08
CN115697382A (zh) 2023-02-03
IT202000005011A1 (it) 2021-09-09
AU2021235546A1 (en) 2022-09-08
JP2023517327A (ja) 2023-04-25
IL295528A (en) 2022-10-01
IL295525A (en) 2022-10-01
WO2020250209A2 (en) 2020-12-17
CA3174733A1 (en) 2021-09-16
CN115279397A (zh) 2022-11-01
JP2023516461A (ja) 2023-04-19
BR112022017243A2 (pt) 2022-10-18
MX2022010870A (es) 2023-01-04
WO2020250209A3 (en) 2021-02-18
EP4117710A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
BR112022017308A2 (pt) Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral
BR112016026556A8 (pt) inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
PH12019502725A1 (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
WO2021191630A8 (en) Coronavirus vaccine
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
BR112012008962A2 (pt) derivados espiro-condensados de ciclohexano como inibidores de hsl úteis para o tratamento de diabetes
CL2015003120A1 (es) Cepas bacterianas que poseen actividad antimicrobiana y composiciones de control biológico que las contienen
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112013002296A2 (pt) composição farmacêutica e respectivo uso e método para tratar doença infecciosa
MX342986B (es) Formulaciones para el tratamiento de las afecciones de las vias aereas superiores.
Lévesque et al. Actinobacillus pleuropneumoniae possesses an antiviral activity against porcine reproductive and respiratory syndrome virus
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
BR112014021065A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor
BR112022019206A2 (pt) Tratamento de infecções por coronavírus
ECSP20084373A (es) Tiofencarboxamidas sustituidas y análogos de las mismas
BR112023017274A2 (pt) Vacina contra metapneumovírus humano
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
BR112022017797A2 (pt) Métodos de distribuição de um bacteriófago, de tratamento de uma infecção bacteriana, de isolamento de um fago direcionado a uma bactéria e composição
PE20090653A1 (es) Formulacion inmunogenica, porque comprende una cepa recombinante atenuada de mycobacterium, preferentemente la cepa recombinante bacilo de calmette y guerin (bcg), que expresa al menos una proteina o fragmento inmunogenico del virus respiratorio sinc
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
BR112022019876A2 (pt) Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
AR106057A1 (es) Composición con efecto antiviral, composición farmacéutica
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
BR112022021423A2 (pt) Uso de proteína surfactante d para tratar infecções virais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.